About TELIX Pharmaceuticals (ASX: TLX)
Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercialising therapeutic and diagnostic radiopharmaceuticals across its three operating segments of Precision Medicine, Therapeutics, and Manufacturing Solutions. The company operates across Australia, Belgium, Canada, the United Kingdom, the United States, and broader international markets, with a strategic collaboration in place with University Hospital Essen.
Its therapeutic pipeline is anchored by TLX591, a lutetium-labeled radio antibody-drug conjugate in a Phase 3 clinical trial for advanced prostate cancer, alongside candidates targeting metastatic kidney cancer, glioblastoma, bone marrow conditioning, soft tissue sarcoma, and bone metastases through programs including TLX250, TLX101, TLX66, TLX592, TLX300, and TLX090. On the diagnostic side, the company markets Illuccix and Gozellix for prostate cancer and is advancing BiPASS through Phase 3 for prostate cancer diagnosis, as well as AlFluor, TLX250-Px, and TLX101-Px as PET imaging agents. Founded in 2015, Telix is headquartered in North Melbourne, Australia.
MFAM Research
No mfam research yet.
Latest Announcements
- TELIX Pharmaceuticals (ASX: TLX) – Telix Releases HY26 Results PresentationAugust 20, 2026I need the actual announcement content to write this properly. The text you’ve provided contains only the title page and forward-looking statement boilerplate—the presentation agenda lists financial updates, precision medicine updates, and therapeutics updates, but the details aren’t included. To write a 400-500 word analyst commentary with specific numbers and details as requested, I need […]
- TELIX Pharmaceuticals (ASX: TLX) – Telix Announces Half Year 2026 ResultsAugust 20, 2026Telix Pharmaceuticals delivered strong H1 2026 results that underscore the company’s ability to execute commercially while advancing a late-stage pipeline. Group revenue reached US$477 million, representing 22% year-over-year growth and tracking toward the upper end of full-year guidance of US$950 million to US$970 million. The performance is particularly noteworthy given that it was achieved alongside […]
- TELIX Pharmaceuticals (ASX: TLX) – Files HY26 Interim Report and Appendix 4DAugust 20, 2026Telix Pharmaceuticals has swung to a half-year profit of $38.3 million, compared with a loss of $2.3 million in the prior year period, marking a significant milestone for the nuclear medicine company as it scales commercialisation of its imaging products in the United States. The turnaround reflects strong revenue momentum, with sales climbing 22 percent […]
- TELIX Pharmaceuticals (ASX: TLX) – Q2 2026 Strong Revenue and Pipeline ProgressJuly 21, 2026Telix Pharmaceuticals delivered solid second-quarter results that underscore its execution capabilities and market position in precision medicine. The company reported revenue of US$247 million, representing growth of 7% quarter-over-quarter and 21% year-over-year, with Precision Medicine segment leading the charge at US$202 million, up 30% year-over-year. This performance trajectory positions Telix to exceed US$1 billion in […]
- TELIX Pharmaceuticals (ASX: TLX) – FDA Alignment Advances ProstACT Global Phase 3July 2, 2026Telix Pharmaceuticals has achieved a significant regulatory milestone with US FDA alignment to advance its ProstACT Global Phase 3 trial into Part 2, a development that substantially de-risks the company’s lead radiopharmaceutical candidate TLX591-Tx for metastatic castration resistant prostate cancer. The FDA’s confirmation that Part 1 safety and dosimetry data supports progression into the randomized […]
- TELIX Pharmaceuticals (ASX: TLX) – Convertible Bond Cleansing Notice FiledApril 20, 2026Telix Pharmaceuticals has lodged a cleansing notice with the ASX regarding its recently announced US$600 million convertible bond offering, a regulatory filing that clears the way for future share issuance without requiring a prospectus. The company priced the convertible notes on April 15, 2026, with the bonds carrying a 1.50% coupon and maturing in 2031. […]
- TELIX Pharmaceuticals (ASX: TLX) – Telix Raises $600M via Convertible BondsApril 15, 2026Telix Pharmaceuticals has successfully priced and upsized its convertible bonds offering to US$600 million, up from the initially planned US$550 million, reflecting strong investor demand for the biopharmaceutical company’s debt instrument. The 1.50 per cent convertible notes due 2031 will be issued through Telix’s wholly-owned subsidiary and guaranteed by Telix and its US operating entity, […]
- TELIX Pharmaceuticals (ASX: TLX) – Telix Presents Investor Update April 2026April 14, 2026Telix Pharmaceuticals has released an investor presentation dated April 14, 2026, highlighting clinical progress with TLX101-Tx (Iodofalan 131I), its investigational LAT1-targeted therapy for glioblastoma. The presentation features a published case study in the European Journal of Nuclear Medicine and Molecular Imaging demonstrating a patient with recurrent glioblastoma who achieved near-complete response following treatment with the […]
- TELIX Pharmaceuticals (ASX: TLX) – Telix Refinances Convertible Bond DebtApril 14, 2026Telix Pharmaceuticals has launched a US$550 million convertible bonds offering due 2031 to refinance its existing convertible bonds maturing in 2029. The move represents a proactive capital management decision by the pharmaceutical company, which continues to demonstrate its ability to access debt markets despite operating in the competitive biopharmaceutical sector. The new convertible bonds will […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Biotechnology |
|---|---|